Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
NEW YORK (Reuters Health) – In patients with unresectable pancreatic cancer, the combination of gemcitabine and a novel cationic liposomal formulation of paclitaxel called EndoTAG-1 substantially prolongs survival…
NEW YORK (Reuters Health) – In a phase III study of patients with progressive well-differentiated pancreatic islet cell tumors, treatment with the tyrosine kinase inhibitor sunitinib significantly prolonged…
NEW YORK (Reuters Health) – As the number of African Americans in a given US county increases, the number of specialists involved in colorectal cancer care decreases, according…
NEW YORK (Reuters Health) – Survivors of Hodgkin’s lymphoma are to 2- to 3-times more likely to experience a stroke or TIA compared with people in the general…
NEW YORK (Reuters Health) – Even a short period of 4 to 8 weeks of smoking cessation prior to surgery to treat upper aerodigestive tract squamous cell carcinoma…
NEW YORK (Reuters Health) – Statin therapy is associated with a reduced risk of hepatocellular carcinoma in patients with diabetes, according to a report in the June issue…
NEW YORK (Reuters Health) – Treatment of prostate cancer with androgen deprivation therapy is associated with an excess risk of incident diabetes and fractures, but not MI or…
Joe Minniti, the Executive Director of the Cancer Foundation for Personal Appearance and Larry Cohen, Executive Vice President of the NIA Group, talk about the NIA group’s support…
Michael Banks, MD, provides an overview of diffuse brainstem gliomas. This video is dedicated to the memory of Max Scotti. About Making Headway Foundation Making Headway® is a…
NEW YORK (Reuters Health) – Initiating second-line chemotherapy for ovarian cancer recurrence based on an increase in the tumor marker CA125 alone does not improve overall survival compared…
